Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — AmpliPhi Biosciences — Merger or Acquisition (January 2019)
18 slides from Armata Pharmaceuticals's merger presentation, Jan 7, 2019
Slide 1: Advancing bacteriophage therapeutics for patients with antibiotic-resistant infections
Advancing bacteriophage therapeutics for patients with antibiotic - resistant infections January 7, 2019 NYSE American: APHB
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - lo
Slide 3: Important Information for Investors and Shareholders
Important Information for Investors and Shareholders This communication may be deemed to be solicitation material in respect of the proposed transaction between AmpliPhi and C 3 J Therapeutics, Inc . ("C 3 J") . In connection with the proposed transaction between AmpliPhi and C 3 J, AmpliPhi will fi
Slide 4: Solving the Antibiotic Resistance Crisis: AmpliPhi and C3J Merger
SOLVING THE ANTIBIOTIC RESISTANCE CRISIS AmpliPhi Biosciences and C3J Therapeutics Merger AmpliPhi and C3J are combining businesses to build the World’s Leading Bacteriophage Company 4
Slide 5: Combined Company: A World-Leader in Phage Therapeutics
Phage platforms led by seasoned drug development team • Robust natural phage discovery library • Synthetic biology to improve pharmacology and path to commercialization • Phage - specific GMP drug manufacturing capabilities (key differentiator) Robust pipeline with high impact clinical stage candida
Slide 6: Overview of the Merger Transaction
Overview of the Merger Transaction • Announced on January 4, 2019 • AmpliPhi will combine with C3J in a stock - for - stock transaction • Current C3J shareholders to own approximately 70% of combined company; current AmpliPhi securityholders to own approximately 30%; ownership split prior to new cap
Slide 7: Leadership Team of the Combined Company
Leadership Team of the Combined Company 7 • Former President & COO, ID Biomedical Corp (Acquired by GSK for $1.5 billion) Todd R. Patrick, MBA Chief Executive Officer • 18 years Amgen (Executive Director Research) • 10 years at Biotech start - ups Brian Varnum, PhD President & Chief Development Offi
Slide 8: Introduction to Bacteriophage (Phage)
Introduction to Bacteriophage (Phage) • The most abundant life form on Earth • Natural predators of bacteria • Highly targeted, exists in harmony with prey • Specific phage engineering can enhance their killing ability, lowers resistance • Low cost of goods • Low cost to manufacture a dose • Replica
Slide 9: Unmet Need in Antibiotic Resistant Infections
Unmet Need in Antibiotic Resistant Infections Phages Provide a Solution to an Urgent Public Health Threat Emergence of Drug - Resistant Bacterial Infections • The incidence of antibiotic - resistant continues to increase, representing a major challenge to human health • 2 million antibiotic - resist
Slide 10: FDA Backs Efforts to Advance New Innovations
10 FDA Backs Efforts to Advance New Innovations Supports Development of Phages as Non - Traditional Antimicrobials Source: Twitter Sept. 16, 2018; ”As more and more bacteria grow resistant to currently available antibiotics, we must tackle the issue on all fronts and seek new approaches to this pers
Slide 11: Combined Pipeline: Multiple Opportunities for Value Creation
Combined Pipeline Multiple Opportunities for Value Creation 11
Slide 12: Lead Indication: S. aureus Bacteremia
12 • CDC estimates that 1.5 million Americans develop bacteremia each year and ~250,000 deaths occur as a direct result of infection 1 • 1 in 3 patients who die in hospital have bacteremia 1 • Bacteremia is the most expensive condition treated at U.S. hospitals, costing ~$24 billion annually 2 • S.
Slide 13: AB-SA01 Ready for Phase 1/2 trial in S. aureus bacteremia
13 AB - SA01 Ready for Phase 1/2 trial in S. aureus bacteremia - 3 lytic phages - 3 ¨ 109 PFU per dose - Covers ~95% S. aureus strains, incl. MDR » Expanded Access: treated 15 patients with serious infections not responding to antibiotics • Bacteremia, endocarditis, PJI, LVAD infections, other • 300
Slide 14: Second Indication: Respiratory Infections
14 First priority clinical candidates • P. aeruginosa synthetic phage candidate • Covers ~20% of hospitalized pneumonia • Major predictor of morbidity and mortality in CF patients • S. aureus synthetic phage candidate • Covers ~30 - 40% of hospitalized pneumonia Address additional respiratory market
Slide 15: Synthetic Pseudomonas Phage Lead Candidate Enhanced Pharmacology
Synthetic Pseudomonas Phage Lead Candidate Enhanced Pharmacology 15 Antibiotic MIC Improvement Over Natural Phage None >1,000 - fold Meropenem >10,000 - fold Ceftazidime >100,000 - fold Additional benefit with antibiotic co - therapy Improved Potency Against MDR Pa With Dramatically Lower MICs Robus
Slide 16: Potential New Indications and Market Expansion
16 Potential New Indications an d Market Expansion Source: GlobaData ; PharmaPoint ; Valamont ; Nature Reviews: Microbiology; 13: 269 - 284; PLoSONE; 9(1): e86634; Postgraduate Medicine; 129 (2): 242 - 258; The Journal of Arthroplasty; 27(8): S1; CMAJ Open DOI:10.9778/cmajo.20160074; Journal of Hosp
Slide 17: Expected Milestones: 2019-2020
17 Expected Milestones: 2019 - 2020 Multidrug - Resistant Infectious Disease • AB - SA01 • Initiate Phase 1/2 clinical study in bacteremia • Synthetic Pseudomonas phage candidate • Transition to GMP manufacturing • Conduct Pre - IND meeting and file IND • Initiate first - in - human clinical study i
Slide 18: Investment Highlights
Investment Highlights • Platforms led by seasoned drug development team • Robust pipeline with high impact clinical stage candidates • Strong Board and Executive leadership team • Strong balance sheet with approximately $18 million in cash at closing • Multiple near - term regulatory milestones • Op
AmpliPhi Biosciences — Merger or Acquisition (January 2019) on 6ix